1 - 2 / 2 ![]() ![]() ![]() ![]() |
1. Treatment response to SGLT2 inhibitors Jasna Klen, Vita Dolžan, 2021, pregledni znanstveni članek Ključne besede: SGLT2 inhibitors, cardiovascular safety, renal safety, genetic polymorphisms |
2. Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus and obesity Jasna Klen, Vita Dolžan, 2022, pregledni znanstveni članek Ključne besede: type 2 diabetes mellitus, obesity, GLP‐1 receptor agonists, incretins, cardiovascular safety, genetic polymorphisms |